Background
==========

Lung cancer is the second most commonly diagnosed malignancy in men and the third most commonly diagnosed malignancy in women worldwide.[@b1-cmar-10-6897] Lung cancer can be classified two major histological groups: small cell lung cancer and non-small-cell lung cancer (NSCLC). NSCLC accounts for more than 80% of all lung cancers, whereas 15%--20% is small cell lung cancer.[@b2-cmar-10-6897],[@b3-cmar-10-6897] NSCLC includes adenocarcinoma (ADC), squamous cell carcinoma (SCC), and large-cell carcinoma, within them, ADC accounts for 40%, SCC for 25%--30%, and large-cell carcinoma for 10%--15%.[@b4-cmar-10-6897],[@b5-cmar-10-6897] Lung carcinogenesis is related to silencing of tumor suppressor genes and activation of oncogenes. Accumulating data indicate that hypermethylation in CpG-rich promoter regions of many suppressor genes can contribute to the development and progression of a variety of cancers.[@b6-cmar-10-6897],[@b7-cmar-10-6897]

Deiss and Kimchi discovered a large group of new genes by using "technical knock-out (TKO) and rescue" screen.[@b8-cmar-10-6897] Those genes function as positive mediators of cell death pathways, therefore they were named "Death-Associated Protein or DAP genes.[@b9-cmar-10-6897] One of the genes isolated by the TKO approach encoded a calcium calmodulin regulated serine/threonine kinase and was named DAP kinase (DAPk1 or DAPK).[@b10-cmar-10-6897],[@b11-cmar-10-6897] Further investigation indicated that DAPK plays an important role in apoptotic and autophagic cell death,[@b12-cmar-10-6897]--[@b14-cmar-10-6897] tumor progression suppression, and metastasis suppression.[@b15-cmar-10-6897]--[@b19-cmar-10-6897] Last two decades, a number of studies showed that DAPK loss by its promoter hypermethylation was associated with the development and progression of NSCLC. However, the results from individual studies were inconsistent due to small size of samples. In the present study, 28 relevant studies were pooled, and a meta-analysis was performed to evaluate the clinicopathological significance of DAPK promoter hypermethylation in NSCLC.

Methods
=======

Search strategy and selection criteria
--------------------------------------

The following electronic databases were screened for relevant articles without any language restrictions: PubMed (1966--2018), Embase (1980--2018), Web of Science (1945--2018), Cochrane Library Database (1972--2018). We used the following keywords: "DAPK methylation", "NSCLC", "Non-small-cell lung cancer", and "lung cancer". A search of PubMed yielded 65 articles, Embase yielded 101, and Web Science yielded 138 articles. The included criteria were as follows: (1) the association between DAPK methylation and the clinicopathological significance of NSCLC; (2) the association of DAPK and prognosis in patients with NSCLC. After screening by titles and abstracts, 38 relevant articles were included for full text review. The following exclusion criteria were used: (1) the same population or overlapping database; (2) conference abstracts containing insufficient data reviews, editorials, letters, case reports, and expert opinion; (3) the studies utilized cell lines. After evaluation, 28 articles fulfilled the entry criteria of this meta-analysis. The detailed information of 28 relevant articles was listed in [Table 1](#t1-cmar-10-6897){ref-type="table"}.

Data extraction and study assessment
------------------------------------

Two reviewers (YZ and JW) extracted data from selected studies independently by using a standardized data extraction form including the following items: first author's name, year of publication, country, number of patients, histology, stage of NSCLC, smoking status of patients with NSCLC, method for methylation detection. Any disagreement was discussed and reached a consensus for all issues.

Statistical analysis
--------------------

ORs with 95% confidence intervals (CIs) were calculated by using a fixed or random effect model depending on heterogeneity (a fixed effect model for *I*^2^\<50%, a random effect model for *I*^2^\>50%). The analysis was performed to compare DAPK promoter hypermethylation between NSCLC and normal tissue, DAPK promoter hypermethylation in different stage of NSCLC, DAPK promoter hypermethylation in different histology type of NSCLC, as well as in smoker and nonsmoker patients with NSCLC. All *P*-values were two sided. *P*-value less than 0.05 was considered statistically significant. Funnel plots were used for detection of publication bias. All analysis was performed with Review Manager 5.2.

Results
=======

In total, 28 studies were included in the present study after screening 304 articles by two reviewers ([Figure 1](#f1-cmar-10-6897){ref-type="fig"}). The following items were collected from each study: first author, published year, country, histology of NSCLC, and DAPK hypermethylation status, smoking status as well as patient prognosis ([Table 1](#t1-cmar-10-6897){ref-type="table"}).

The total number of NSCLC tumor from 28 studies is 2148, 870 of them were with DAPK promoter hypermethylated, the rate was 40.50%. Whereas the promoter hyper-methylation rate from individual study ranged from 10.99% to 83.13% ([Table 1](#t1-cmar-10-6897){ref-type="table"}). The frequency of DAPK promoter hypermethylation was significantly higher in NSCLC than in non-malignant lung; and the pooled OR was 5.69 with 95% CI 3.44--9.39, *Z*=6.79, *P*\<0.00001 ([Figure 2](#f2-cmar-10-6897){ref-type="fig"}). DAPK promoter methylation was similar between SCC and ADC; the pooled OR was 1.30 with 95% CI 0.96--1.74, *Z*=1.71, *P*=0.09, *I*^2^=0% ([Figure 3](#f3-cmar-10-6897){ref-type="fig"}). In addition, DAPK methylation was not significantly correlated with stages of NSCLC; OR was 0.78 with 95% CI 0.54--1.13, *Z*=1.29, *P*=0.20, *I*^2^=0% ([Figure 4](#f4-cmar-10-6897){ref-type="fig"}). The rate of DAPK methylation was not associated with smoking behavior in patients with NSCLC; OR was 1.11 with 95% CI 0.80--1.54, *Z*=0.62, *P*=0.53, *I*^2^=18% ([Figure 5](#f5-cmar-10-6897){ref-type="fig"}). However, DAPK promoter hypermethylation was significantly associated with poor prognosis in patients with NSCLC; HR was 1.25 with 95% CI 1.06--1.46, *Z*=2.68, *P*=0.007, *I*^2^=0% ([Figure 6](#f6-cmar-10-6897){ref-type="fig"}).

The quality of each study was assessed using the New-castle Ottawa Quality Assessment Scale (NOQAS). This scale for non-randomized case controlled studies and cohort studies was used to allocate a maximum of nine points for the quality of selection, comparability, exposure, and outcomes for study participants. Of the studies, 15 scored eight points, 11 scored seven points, and two scored six points (data not shown). Hence, the studies were of a relatively high quality. A sensitivity analysis, in which one study was removed at a time, was conducted to assess the result stability. The pooled ORs were not significantly changed, indicating the stability of our analyses (data not shown). The funnel plots were largely symmetric ([Figure 7](#f7-cmar-10-6897){ref-type="fig"}), suggesting there were no publication biases in the meta-analysis of DAPK promoter hypermethylation and clinicopathological features.

Discussion
==========

Aberrant methylation in tumor suppressor genes has been linked to carcinogenesis. Hypermethylation is the predominant mechanism to make tumor suppressor genes silent by promoter inactivation. DAPK gene is located on chromosome 9q34.1. It encodes a proapoptotic protein involved in apoptosis initiated by THN-α, IFN-γ, Fas, and TRAIL. DAPK promoter methylation has been observed in about 30 types of tumor including NSCLC. Moreover, aggressiveness of malignant tumors has been associated with the methylation of the promoter region of the DAPK gene and loss of DAPK expression.[@b20-cmar-10-6897] A number of studies evaluated the methylation rate in NSCLC, which ranged from 10.99% to 83.33% due to small size of samples. We pooled 28 studies including 2,148 NSCLC patients, 870 of them were with DAPK gene promoter hypermethylated; hypermethylation rate was 40.50%, 5.69 times higher than the one in non-malignant lung tissue. Therefore, DAPK promoter hypermethylation was correlated with the risk of NSCLC. Previous evidence indicated that the expression of DAPK was partially restored by treatment with a demethylation agent, 5′-aza-2′-deoxycitidine.[@b15-cmar-10-6897] DAPK could be a potential target for development of new strategy of treatment.

We did not find significant association of DAPK promoter hypermethylation with tumor histology, smoking, and stage. Although TNM staging system still remained the most powerful tool for medical decision making, it is difficult to accurately predict the prognosis for individual patient. The 5-year survival rate for patients with stage I NSCLC is about 65%--80%,[@b21-cmar-10-6897] therefore a more accurate tool, independent from TNM stage, is very important to predict prognosis in those patients. Our finding indicated that DAPK was correlated to worse survival in our meta-analysis, supporting the importance of epigenetic gene regulation in NSCLC progression and prognosis. Loss of apoptotic functions would compromise cell death induced by unrepaired DNA damage.[@b22-cmar-10-6897] In addition, DAPK promoter hypermethylation is associated with metastatic status. Taken together, DAPK promoter hypermethylation leads to worse prognosis in patients with NSCLC. DAPK hypermethylation is a potential predictor of survival in patients with NSCLC.

Given the important role of smoking in the development of lung cancer and the fact that DNA methylation is an early event in carcinogenesis,[@b23-cmar-10-6897] several biomarker such as Wnt inhibitory factor-1 (Wif1), Phosphatase and tensin homologue deleted on chromosome 10 (PTEN), and TP53 were associated with smoking behavior.[@b24-cmar-10-6897]--[@b27-cmar-10-6897] However, no correlation was found between DAPK promoter hypermethylation and the smoking behavior in the present study. Further confirmation needs to be finished in future when more relative studies are available.

Our findings should be interpreted in view of certain limitations. First, most of the included studies were retrospective, 26 out of 28 were of sufficient quality (NOQAS ≥ 7). Hence, the studies were of a relatively high quality. Although the possibility of selection, sample, and publication bias could not be excluded, no obvious bias was detected by the funnel plots. Second, present findings were based on individual unadjusted ORs and further confirmation needs to be finished by evaluation adjusted with other potential risk factors.

Conclusion
==========

In summary, present findings suggested that DAPK promoter hypermethylation was correlated with the risk of NSCLC; and DAPK is a promising drug target for development of new therapy strategy. Additionally, DAPK promoter hyper-methylation was a potential predictor of poor prognosis in patients with NSCLC.
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![Forest plot for DAPK promoter hypermethylation in NSCLC and non-malignant lung tissue.\
**Notes:** The squares represent the weight of individual study in the meta-analysis, the line width indicates the corresponding 95% CI, the diamond represents the pooled OR, and the width of diamond indicates 95% CI.\
**Abbreviations:** DAPK, death-associated protein kinase; M--H, Mantel--Haenszel; NSCLC, non-small-cell lung cancer.](cmar-10-6897Fig2){#f2-cmar-10-6897}

![Forest plot for DAPK promoter hypermethylation in SCC and ADC.\
**Notes:** The squares represent the weight of individual study in the meta-analysis, the line width indicates the corresponding 95% CI, the diamond represents the pooled OR, and the width of diamond indicates 95% CI.\
**Abbreviations:** ADC, adenocarcinoma; DAPK, death-associated protein kinase; M--H, Mantel--Haenszel; NSCLC, non-small-cell lung cancer; SCC, squamous cell carcinoma.](cmar-10-6897Fig3){#f3-cmar-10-6897}

![Forest plot for DAPK promoter hypermethylation in NSCLC stage III/IV and stage I/II.\
**Notes:** The squares represent the weight of individual study in the meta-analysis, the line width indicates the corresponding 95% CI, the diamond represents the pooled OR, and the width of diamond indicates 95% CI.\
**Abbreviations:** DAPK, death-associated protein kinase; M--H, Mantel--Haenszel; NSCLC, non-small-cell lung cancer.](cmar-10-6897Fig4){#f4-cmar-10-6897}

![Forest plot for DAPK promoter hypermethylation in NSCLC patients with smoking and non-smoking behavior.\
**Notes:** The squares represent the weight of individual study in the meta-analysis, the line width indicates the corresponding 95% CI, the diamond represents the pooled OR, and the width of diamond indicates 95% CI.\
**Abbreviations:** M--H, Mantel--Haenszel; NSCLC, non-small-cell lung cancer.](cmar-10-6897Fig5){#f5-cmar-10-6897}

![Forest plot for the association of DAPK promoter hypermethylation and the overall survival of NSCLC patients.\
**Notes:** The squares represent the weight of individual study in the meta-analysis, the line width indicates the corresponding 95% CI, the diamond represents the pooled OR, and the width of diamond indicates 95% CI.\
**Abbreviations:** DAPK, death-associated protein kinase; NSCLC, non-small-cell lung cancer; SE, standard error.](cmar-10-6897Fig6){#f6-cmar-10-6897}

![Funnel plot for publication bias.\
**Notes:** (**A**) DAPK promoter hypermethylation in NSCLC and non-malignant lung tissue; (**B**) DAPK promoter hypermethylation in SCC and ADC; (**C**) DAPK promoter hypermethylation in NSCLC stage III/IV and stage I/II. (**D**) DAPK promoter hypermethylation in NSCLC patients with smoking and non-smoking behavior; (**E**) the association of DAPK promoter hypermethylation and the overall survival of NSCLC patients. Area of the circle represents the weight of individual study.\
**Abbreviations:** ADC, adenocarcinoma; DAPK, death-associated protein kinase; NSCLC, non-small-cell lung cancer; SCC, squamous cell carcinoma; SE, standard error.](cmar-10-6897Fig7){#f7-cmar-10-6897}

###### 

Main characteristics of included studies

  Study                                       Year    Country     Sample size (M/T)   DAPK methylation rate (%)   Histology   Stage (TNM)   Smoking status   Method                             
  ------------------------------------------- ------- ----------- ------------------- --------------------------- ----------- ------------- ---------------- -------- ------- -------- -------- -------
                                                                                                                                                                                                
  Ali et al[@b28-cmar-10-6897]                2017    India       133/160             83.13                       49/70       --            --               --       --      --       --       MSP
  Jin et al[@b29-cmar-10-6897]                2016    China       120/199             60.30                       --          55/95         65/104           --       --      94/145   26/54    MSP
  Guo et al[@b30-cmar-10-6897]                2015    China       35/202              17.33                       --          15/111        20/91            16/100   5/27    --       --       MSP
  Kontic et al[@b31-cmar-10-6897]             2012    Serbia      11/47               23.40                       --          4/18          7/29             10/35    2/18    1/11     11/44    MSP
  Fujii et al[@b32-cmar-10-6897]              2012    Japan       6/46                13.04                       0/25        --            --               --       --      --       --       MSP
  Zhang et al[@b33-cmar-10-6897]              2011    China       120/200             61.00                       23/200      --            --               --       --      --       --       MSP
  Zhang et al[@b34-cmar-10-6897]              2010    China       11/78               14.10                       3/78        --            --               --       --      --       --       MSP
  Jin et al[@b35-cmar-10-6897]                2010    China       88/150              58.67                       15/150      --            --               --       --      --       --       MSP
  Peng et al[@b36-cmar-10-6897]               2010    China       48/82               58.54                       0/25        --            --               --       --      --       --       MSP
  Niklinska et al[@b37-cmar-10-6897]          2009    Japan       22/61               36.07                       --          --            --               --       --      --       --       MSP
  Han et al[@b38-cmar-10-6897]                2009    USA         8/14                57.14                       4/20        --            --               --       --      --       --       MSP
  Licchesi et al[@b39-cmar-10-6897]           2008    USA         7/19                36.8                        0/46                                                                          MSP
  Katayama et al[@b40-cmar-10-6897]           2007    Japan       --                                              --          --            --               2/8      8/26    --       --       MSP
  Yanagawa et al[@b41-cmar-10-6897]           2007    Japan       26/101              25.74                       8/101       14/62         12/39            20/75    6/26    20/73    6/28     MSP
  Liu et al[@b42-cmar-10-6897]                2007    China       40/122              32.79                       --          25/72         15/50            17/54    17/54   28/81    12/41    MSP
  Belinsky et al[@b43-cmar-10-6897]           2007    USA         22/72               30.56                       5/25        --            --               --       --      --       --       MSP
  Fischer et al[@b44-cmar-10-6897]            2007    Germany     --                                              --          --            --               --       --      --       --       MSP
  Kim et al[@b45-cmar-10-6897]                2005a   Korea       23/72               31.94                       4/72        --            --               --       --      --       --       MSP
  de Fraipont et al[@b46-cmar-10-6897]        2005    France      --                                              --          --            --               --       --      18/121   1/4      MSP
  Safar et al[@b47-cmar-10-6897]              2005    USA         12/32               37.50                       6/32        --            --               16/48    8/57    --       --       MSP
  Russo et al[@b48-cmar-10-6897]              2005    USA         22/49               44.90                       1/27        --            --               --       --      --       --       MSP
  Kim et al[@b49-cmar-10-6897]                2005b   Korea       --                                              --          13/42         7/17             9/34     9/27    --       --       MSP
  Fujiwara et al[@b50-cmar-10-6897]           2005    Japan       10/91               10.99                       5/100       --            --               6/60     4/31    9/43     10/38    MSP
  Divine et al[@b51-cmar-10-6897]             2005    USA         72/206              34.95                       --          --            --               --       --      16/45    45/125   MSP
  Lu et al[@b19-cmar-10-6897]                 2004    USA         --                                              --          --            --               --       --      --       --       MSP
  Toyooka et al[@b52-cmar-10-6897]            2003    USA         14/38               36.84                       1/15        8/20          6/18             --       --      --       --       COBRA
  Soria et al[@b53-cmar-10-6897]              2002    USA         --                                              --          --            --               --       --      13/89    4/11     MSP
  Zöchbauer-Müller et al[@b54-cmar-10-6897]   2001    Australia   20/107              18.69                       6/104       7/45          9/43             17/82    3/25    18/98    2/9      MSP

**Abbreviations:** ADC, adenocarcinoma; COBRA, combined bisulfite restriction analysis; DAPK, death-associated protein kinase; M, number of NSCLC with methylation; MSP, methylation-specific PCR; NCT, normal control tissue; NSCLC, non-small-cell lung cancer; SCC, squamous cell cancer; T, total number of NSCLC.
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